Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia Clinical research trials and Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia. Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia clinical trial. Human subjects often get the best healthcare possible for their Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "C" Clinical Trials Conditions > Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia



Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

For Condition: childhood acute myeloid leukemia in remission,childhood acute promyelocytic leukemia (M3),adult acute myeloid leukemia in remission,adult acute promyelocytic leukemia (M3)
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and monoclonal antibody in treating patients who have acute promyelocytic leukemia.
Details: OBJECTIVES: - Determine the disease-free and overall survival of patients with acute promyelocytic leukemia in clinical complete remission following tretinoin-based induction therapy treated with monoclonal antibody HuG1-M195, arsenic trioxide, idarubicin, and tretinoin. - Determine the rate of molecular complete remission in patients treated with this regimen. - Determine the toxicity of this regimen in this patient population. - Determine the number and length of hospitalizations of patients treated with this regimen. OUTLINE: Patients receive monoclonal antibody HuG1-M195 (MOAB HuM195) IV over 40-60 minutes twice weekly for 3 weeks. Approximately 2-4 weeks after completion of MOAB HuM195, patients receive arsenic trioxide IV over 1-4 hours daily for a total of 25 days with no more than 5 days between doses. Beginning approximately 4-6 weeks after completion of arsenic trioxide, patients receive idarubicin IV daily on days 1-3 or 1-4 and filgrastim (G-CSF) subcutaneously daily beginning on day 5 or 6 and continuing until blood counts recover. Treatment repeats every 4 weeks for patients who remain RT-PCR positive or are newly converted to RT-PCR negative (molecular complete remission) following a prior course of idarubicin for a maximum of 3 courses. Patients who remain RT-PCR positive following course 3 of idarubicin receive no further treatment on study. Beginning 3 months after completion of idarubicin, patients in molecular complete remission receive oral tretinoin daily for 14 days. Treatment repeats every 3 months for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed monthly. PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study within 2-3 years.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of acute promyelocytic leukemia by positive RT-PCR assay for PML/RAR-alfa rearrangement or a t(15;17) karyotype - Achieved clinical complete remission within the past 1-2 months - Prior induction therapy must have contained tretinoin - No other acute myeloid leukemia diagnosis PATIENT CHARACTERISTICS: Age: - Any age Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Bilirubin less than 2 mg/dL - Transaminases no greater than 3 times upper limit of normal Renal: - Creatinine less than 2 mg/dL OR - Creatinine clearance greater than 60 mL/min Cardiovascular: - Ejection fraction normal or greater than 50% by echocardiogram or MUGA Other: - No other concurrent active malignancy - No other serious or life-threatening condition that would preclude study - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 4 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics - At least 1 week since prior retinoids Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified Other: - No prior postremission therapy of any form
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
JosephJurcic,  Study Chair,  Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City,  New York,  10021
United States
Recruiting Joseph  Jurcic 212-639-2955


Additional Information:
Study ID Numbers:  CDR0000068600;  NCI-H01-0073,MSKCC-00072
Study Start Date: 
Record last reviewed: September 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00016159

Other Childhood Acute Promyelocytic Leukemia (m3) Studies:
1. Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

2. Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

3. Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission

4. Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Low-Dose Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

Related Studies:

Other childhood acute promyelocytic leukemia (M3) Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Modify your Search

  Other childhood acute promyelocytic leukemia (M3) Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103